Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors

Clinical trial NCT04172454 · COMPLETED

Trial details

NCT number: NCT04172454
Sponsor: Akeso
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumors Melanoma

Start date: 2019-12-20
Primary completion: 2021-06-17
Enrollment: 68

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.